Method for reducing measurement error in latex agglutination immunoassay

Patent metadata

Field	Value
Publication number	US-11668708-B2
Application number	US-201716651872-A
Country	US
Kind code	B2
Filing date	Sep 29, 2017
Priority date	Sep 29, 2017
Publication date	Jun 6, 2023
Grant date	Jun 6, 2023

Abstract

A method for avoiding the influence of a blood sample on a measurement error in a latex agglutination immunoassay. The measurement error caused by a blood sample in a latex agglutination immunoassay can be reduced by a method which includes a step of bringing the sample into contact, in a liquid phase, with latex particles carrying a substance having a specific affinity for an analyte in the presence of imidazole.

First claim

The invention claimed is:

1. A method for measuring an analyte in a chylous plasma or chylous serum by a latex agglutination immunoassay, comprising the following steps:
(1) bringing a chylous plasma or chylous serum containing chyle into contact with imidazole or an imidazole derivative, or a salt thereof in a liquid phase;
(2) adding latex particles carrying a substance having a specific affinity for the analyte to the liquid phase sequentially after the step (1); and
(3) measuring an agglutination reaction between the analyte and the latex particles after the step (2), without performing a cleaning or separation step during or after the step (2),
wherein the concentration of imidazole or an imidazole derivative, or a salt thereof in the step (3) of measuring the agglutination reaction of the latex particles is not less than 100 mM and not more than 375 mM.

2. A method for measuring an analyte in a chylous plasma or chylous serum by a latex agglutination immunoassay, comprising the following steps:
(1) bringing a chylous plasma or chylous serum into contact with imidazole or an imidazole derivative, or a salt thereof in a liquid phase;
(2) adding latex particles carrying a substance having a specific affinity for the analyte to the liquid phase after the step (1); and
(3) measuring an agglutination reaction between the analyte and the latex particles after the step (2), without performing a cleaning or separation step prior to the measurement step (3),
wherein the concentration of imidazole or an imidazole derivative, or a salt thereof in the step (3) of measuring the agglutination reaction of the latex particles is not less than 100 mM and not more than 375 mM.

3. The method according to claim 1 ,
wherein said step of bringing a chylous plasma or chylous serum into contact with imidazole or an imidazole derivative, or a salt thereof in a liquid phase is a step of adding a first reagent to a chylous plasma or chylous serum, thereby producing a first mixture, wherein said first reagent contains a buffer solution containing imidazole or an imidazole derivative, or a salt thereof; and
wherein said step of adding latex particles carrying a substance having a specific affinity for the analyte to the liquid phase is a step of adding a second reagent to the first mixture, wherein said second reagent contains latex particles carrying a substance having a specific affinity for the analyte.

4. The method according to claim 3 , wherein said first reagent is a buffer solution containing imidazole or an imidazole derivative, or a salt thereof.

5. The method according to claim 4 , wherein said second reagent is a suspension of latex particles carrying a substance having a specific affinity for the analyte.

6. The method according to claim 5 , wherein the step of measuring an agglutination reaction between the analyte and the latex particles is a step of measuring an agglutination reaction between an analyte and latex particles without performing a cleaning or separation step during or after the step of adding a suspension of latex particles carrying a substance having a specific affinity for the analyte to the first mixture.

7. The method according to claim 1 , wherein said imidazole or imidazole derivative or salt thereof is selected from the group consisting of imidazole, 1-methylimidazole, 1-ethylimidazole, 1-propylimidazole, 1-butylimidazole, 1-phenylimidazole, 1-vinylimidazole, 1-allylimidazole, 1-benzyl-2-methylimidazole, 1-benzyl-2-formylimidazole, 1-benzyl-4-hydroxymethylimidazole, 1-benzyl-5-hydroxymethylimidazole, 1-(2-hydroxyethyl)-imidazole, 1-(2-hydroxyethyl)-2-methylimidazole, 2-methylimidazole, 2-ethylimidazole, 2-propylimidazole, 2-butylimidazole, 2-phenylimidazole, 2-formylimidazole, 2-hydroxymethylimidazole, 2-methyl-1-vinylimidazole, 2-butyl-4-formylimidazole, 2-butyl-4-hydroxymethylimidazole, 2-butyl-4-chloro-5-formylimidazole, 2-hydroxymethyl-1-benzylimidazole, 2-hydroxymethyl-2-methylimidazole, 2-ethyl-4-methylimidazole, 4-butylimidazole, 4-formylimidazole, 4-formyl-1-methylimidazole, 4-formyl-1-tritylimidazole, 5-formyl-1-methylimidazole, 4-formyl-5-methylimidazole, 4-hydroxymethylimidazole hydrochloride, methylimidazole-4-carboxylate, ethylimidazole-4-carboxylate, 1,2-dimethylimidazole, 1,2,4-trimethylimidazole and a salt of any of said imidazole or imidazole derivatives.

8. The method according to claim 6 , wherein said imidazole or imidazole derivative or salt thereof is selected from the group consisting of imidazole, 1-methylimidazole, 1-ethylimidazole, 1-propylimidazole, 1-butylimidazole, 1-phenylimidazole, 1-vinylimidazole, 1-allylimidazole, 1-benzyl-2-methylimidazole, 1-benzyl-2-formylimidazole, 1-benzyl-4-hydroxymethylimidazole, 1-benzyl-5-hydroxymethylimidazole, 1-(2-hydroxyethyl)-imidazole, 1-(2-hydroxyethyl)-2-methylimidazole, 2-methylimidazole, 2-ethylimidazole, 2-propylimidazole, 2-butylimidazole, 2-phenylimidazole, 2-formylimidazole, 2-hydroxymethylimidazole, 2-methyl-1-vinylimidazole, 2-butyl-4-formylimidazole, 2-butyl-4-hydroxymethylimidazole, 2-butyl-4-chloro-5-formylimidazole, 2-hydroxymethyl-1-benzylimidazole, 2-hydroxymethyl-2-methylimidazole, 2-ethyl-4-methylimidazole, 4-butylimidazole, 4-formylimidazole, 4-formyl-1-methylimidazole, 4-formyl-1-tritylimidazole, 5-formyl-1-methylimidazole, 4-formyl-5-methylimidazole, 4-hydroxymethylimidazole hydrochloride, methylimidazole-4-carboxylate, ethylimidazole-4-carboxylate, 1,2-dimethylimidazole, 1,2,4-trimethylimidazole and a salt of any of said imidazole or imidazole derivatives.

9. The method according to claim 2 , wherein step (1) comprises bringing the chylous plasma or chylous serum into contact with a buffer solution containing imidazole or an imidazole derivative, or a salt thereof.

10. The method according to claim 9 , wherein the latex particles are added in the form of a suspension of latex particles carrying a substance having a specific affinity for the analyte.

11. The method according to claim 10 , wherein the step of measuring an agglutination reaction between the analyte and the latex particles is a step of measuring an agglutination reaction between an analyte and latex particles without performing a cleaning or separation step during or after the step of adding a suspension of latex particles carrying a substance having a specific affinity for the analyte to the first mixture.

12. The method according to claim 2 , wherein said imidazole or imidazole derivative or salt thereof is selected from the group consisting of imidazole, 1-methylimidazole, 1-ethylimidazole, 1-propylimidazole, 1-butylimidazole, 1-phenylimidazole, 1-vinylimidazole, 1-allylimidazole, 1-benzyl-2-methylimidazole, 1-benzyl-2-formylimidazole, 1-benzyl-4-hydroxymethylimidazole, 1-benzyl-5-hydroxymethylimidazole, 1-(2-hydroxyethyl)-imidazole, 1-(2-hydroxyethyl)-2-methylimidazole, 2-methylimidazole, 2-ethylimidazole, 2-propylimidazole, 2-butylimidazole, 2-phenylimidazole, 2-formylimidazole, 2-hydroxymethylimidazole, 2-methyl-1-vinylimidazole, 2-butyl-4-formylimidazole, 2-butyl-4-hydroxymethylimidazole, 2-butyl-4-chloro-5-formylimidazole, 2-hydroxymethyl-1-benzylimidazole, 2-hydroxymethyl-2-methylimidazole, 2-ethyl-4-methylimidazole, 4-butylimidazole, 4-formylimidazole, 4-formyl-1-methylimidazole, 4-formyl-1-tritylimidazole, 5-formyl-1-methylimidazole, 4-formyl-5-methylimidazole, 4-hydroxymethylimidazole hydrochloride, methylimidazole-4-carboxylate, ethylimidazole-4-carboxylate, 1,2-dimethylimidazole, 1,2,4-trimethylimidazole and a salt of any of said imidazole or imidazole derivatives.

13. The method according to claim 11 , wherein said imidazole or imidazole derivative or salt thereof is selected from the group

Assignees

• Sekisui Medical Co Ltd

Inventors

• Fujimura Kengo
• Kondou Junichi
• Yamamoto Mitsuaki

Classifications

• G01N33/536

  with immune complex formed in liquid phase · CPC title

• G01N33/5306 Primary

  Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title

• G01N33/543 Primary

  with an insoluble carrier for immobilising immunochemicals · CPC title

• G01N2458/00

  Labels used in chemical analysis of biological material · CPC title

• G01N33/545

  Synthetic resin · CPC title